Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.43 USD | +4.40% | -1.04% | -26.50% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-26.50% | 3.09B | B | ||
+0.67% | 42.4B | B | ||
+45.83% | 40.04B | A | ||
-6.20% | 28.31B | C | ||
+6.55% | 24.94B | B- | ||
-21.66% | 18.96B | B | ||
+29.96% | 12.3B | C+ | ||
-1.57% | 11.95B | C+ | ||
+16.03% | 11.32B | B+ | ||
-4.80% | 11.55B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FOLD Stock
- Ratings Amicus Therapeutics, Inc.